| In vitro determination of the release of alendronic acid from alendronate tablets of different brands during deglutition. | |
| | |
MedLine Citation:
|
PMID: 19630066 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Alendronic acid, a frequently applied compound for the treatment of different forms of diseases of bone metabolism, is a strong acid with a high solubility in water. In connection with the oral administration this exhibits a potential health risk for the upper gastrointestinal tract. The in vitro release of tablets containing alendronic acid of different brands (Stada, ratiopharm, interpharm, Fosamax) was determined by dissolution tests for the time period required for oral intake. The effect of rotation speed, temperature, and solvent volume on the release rate of alendronic acid was determined for the used dissolution apparatus. Analysis of alendronic acid was performed by a validated HPLC method. The highest rate of release was found for the original brand. The dissolution rate of the generic formulations was significantly lower in the early stage of dissolution. Over the complete range of dissolution, more than 85% of the claimed amount was dissolved within 4 min. Dissolution profiles were compared by calculation of the similarity factor f(2) showing equal products with the exception of one generic product, whose dissolution rate was lower. |
| | |
Authors:
|
Guenther Lamprecht |
Related Documents
:
|
10822016 - A monoclonal antibody-based enzyme-linked immunosorbent assay of ursodeoxycholic acid 3... 19935406 - Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic acid in pa... 3949116 - Effect of ursocholic acid on bile lipid secretion and composition. 8392456 - The revival of nitric acid for the treatment of anogenital warts. 16835106 - Kinetics of chloroform formation from humic and fulvic acid chlorination. 6167216 - Plasma amino-acid concentrations during development in the rat. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of pharmaceutical sciences Volume: 98 ISSN: 1520-6017 ISO Abbreviation: J Pharm Sci Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-08-31 Completed Date: 2010-01-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 2985195R Medline TA: J Pharm Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 3575-81 Citation Subset: IM |
Affiliation:
|
Institute of Analytical Chemistry and Food Chemistry, University of Vienna, Waehringerstrasse 38, A-1090 Vienna, Austria. guenther.lamprecht@univie.ac.at |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alendronate
/
analysis*,
chemistry*,
pharmacokinetics Algorithms Bone Density Conservation Agents / analysis*, chemistry*, pharmacokinetics Chemistry, Pharmaceutical Chromatography, High Pressure Liquid Deglutition Diphosphonates / analysis Drugs, Generic Indicators and Reagents Kinetics Solubility Solvents Tablets Therapeutic Equivalency |
| Chemical | |
Reg. No./Substance:
|
0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Drugs, Generic; 0/Indicators and Reagents; 0/Solvents; 0/Tablets; 40391-99-9/pamidronate; 66376-36-1/Alendronate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Amino acids suppress apoptosis induced by sodium laurate, an absorption enhancer.
Next Document: Pre-treatment predictors and in-treatment factors associated with change in avoidant and dependent p...